Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by analysts at Cowen and Company in a research note issued on Tuesday. They presently have a $100.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s target price indicates a potential upside of 25.93% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Morgan Stanley reiterated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday. Chardan Capital reissued a “buy” rating and set a $131.00 target price (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Monday. Needham & Company LLC reissued a “buy” rating and set a $98.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. Credit Suisse Group set a $96.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Finally, Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $77.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 0.58% during midday trading on Tuesday, hitting $78.95. 853,147 shares of the stock were exchanged. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The stock’s market cap is $6.80 billion. The firm’s 50-day moving average is $73.05 and its 200 day moving average is $53.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by $0.03. The company had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The company’s revenue was up 160.3% on a year-over-year basis. During the same quarter last year, the business earned ($1.21) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals will post ($5.26) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/11/alnylam-pharmaceuticals-inc-alny-rating-reiterated-by-cowen-and-company.html.

In related news, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the sale, the vice president now owns 5,625 shares in the company, valued at approximately $393,750. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Akshay Vaishnaw sold 43,750 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the completion of the sale, the senior vice president now owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is owned by insiders.

Large investors have recently modified their holdings of the stock. Calvert Investment Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 36 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 36 shares during the period. CIBC Asset Management Inc increased its stake in shares of Alnylam Pharmaceuticals by 1.1% in the second quarter. CIBC Asset Management Inc now owns 4,119 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 46 shares during the period. IBM Retirement Fund increased its stake in shares of Alnylam Pharmaceuticals by 1.0% in the second quarter. IBM Retirement Fund now owns 7,559 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 76 shares during the period. Finally, Taylor Wealth Management Partners increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Taylor Wealth Management Partners now owns 31,205 shares of the biopharmaceutical company’s stock valued at $2,938,000 after buying an additional 85 shares during the period. Institutional investors and hedge funds own 89.27% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.